Kankere ya kgeleswa ya setlha e bolaya go le kana kang?
Kankere ya kgeleswa ya setlha ke ya bobedi mo go tsa kankere e e tlwaelegileng thata mo banneng mo lefatsheng lotlhe, ka palo e e fopholediwang go dimilione di le 1,276 tsa dikgetsi tse dintšhwa tse di begilweng ka 2018, e e emelang 7,1% ya dikgetsi tsotlhe tsa kankere mo banneng.
Seelo sa dintsho tsa kankere ya kgeleswa ya setlha le sona se kwa godimo, ka palo e e fopholediwang ya dintsho di le 37 005 mo lefatsheng ka bophara ka 2018.
Le fa go ntse jalo, selekanyo sa dintsho se farologana thata go ya ka kgaolo, ka gore Afrika Bophirima e na le kotsi ya botlhano e e kwa godimo thata ya dintsho tsa kankere ya kgeleswa ya setlha mo lefatsheng, mme Nigeria e na le palo e kgolo ya batho le ikonomi mo kgaolong eno.
Kwa Nigeria, kankere ya kgeleswa ya setlha ke yone kankere e e tlwaelegileng thata le e e bolayang thata mo banneng, e go fopholediwang gore e bolaya banna ba le 32,8 le ba le 16,3 mo banneng ba le 100 000.
Palo eno e feta ya dintsho tse di diragetseng kwa Amerika Bokone gabedi.
Go lemogiwa ga bolwetse jono go setse go le thari, go tlhaela ga didirisiwa tsa go bo tlhatlhoba le go bo lemoga, le go fokotsega ga go kwalwa le go begwa ga batho ba ba tshwerweng ke bolwetse jono go dira gore go nne le dintsho tse dintsi kwa Nigeria.
Kwa United States, kankere ya kgeleswa ya setlha ke yone e e bakang dintsho tsa kankere ya bobedi mo banneng, mme e bolaya banna ba ka nna 40 000 ngwaga le ngwaga.
Palo ya batho ba ba bolawang ke kankere ya kgeleswa ya setlha e ntse e fokotsega ka bonya fa e sa le ka bo1990, mme e sa ntse e le bothata jo bo masisi mo botsogong.
Ka kakaretso, kankere ya kgeleswa ya setlha ke bolwetse jo bo bolayang, segolobogolo mo dikgaolong tse di nang le mathata a go bona kalafi le go tlhatlhobiwa.
Le fa go ntse jalo, go lemoga bolwetse jono ka bonako le go bo alafa go ka tokafatsa ditlamorago tsa jone thata le go fokotsa dintsho.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Go se ikarabele: kalafi']
['Web site eno e diretswe go ruta le go naya tshedimosetso fela mme ga e neye kgakololo ya kalafi kgotsa ditirelo tsa seporofešenale.']
['Tshedimosetso e e neelwang ga e a tshwanela go dirisiwa go bona bolwetse kana go alafa bothata jwa botsogo, mme batho ba ba batlang kgakololo ya kalafi ba tshwanetse go ikgolaganya le ngaka e e nang le laesense.']
['Tsweetswee ela tlhoko gore thulaganyo ya methapo e e dirang dikarabo tsa dipotso tseno, ga e a tlhomama fa go tla mo dilong tsa dipalo. Ka sekai, palo ya batho ba ba nang le bolwetse bongwe jo bo rileng.']
['Ka metlha batla kgakololo ya ngaka ya gago kgotsa moabi yo mongwe wa kalafi yo o tshwanelegang malebana le boemo jwa kalafi. Le ka motlha o se ka wa itlhokomolosa kgakololo ya kalafi ya porofeshenale kgotsa wa diega go e batla ka ntlha ya sengwe se o se badileng mo website eno. Fa o akanya gore o ka tswa o na le boemo jwa tshoganyetso jwa kalafi, leletsa 911 kgotsa o ye kwa kamoreng ya tshoganyetso e e gaufi le wena ka bonako. Ga go na kamano epe ya ngaka le molwetse e e tlisiwang ke website eno kgotsa go e dirisa. BioMedLib kgotsa badiri ba yone, kgotsa ope fela yo o tsentseng letsogo mo website eno, ga ba dire ditshupetso dipe, tse di tlhamaletseng kgotsa tse di sa tlhamalalang, malebana le tshedimosetso e e mo go yone kgotsa go e dirisa.']
['Go ikgatholosa: ditshwanelo tsa bokwadi']
['Molao wa Digital Millennium Copyright wa 1998, 17 U.S.C. § 512 (the DMCA) o tlamela ka kgetse ya beng ba ditshwanelo ba ba dumelang gore matheriale o o tlhagelelang mo inthaneteng o gataka ditshwanelo tsa bona go ya ka molao wa ditshwanelo wa U.S.']
['Fa o dumela ka pelo yotlhe gore tshedimosetso kgotsa matheriale o o mo website ya rona kgotsa ditirelo tsa rona o gataka ditshwanelo tsa gago tsa semolao, wena (kgotsa moemedi wa gago) o ka re romelela kitsiso o kopa gore tshedimosetso eo kgotsa matheriale oo o tlosiwe kgotsa o thibelwe go o fitlhelela.']
['Dikitsiso di tshwanetse go romelwa ka go kwala ka imeili (leba karolo ya "Contact" go bona aterese ya imeili).']
['DMCA e batla gore kitsiso ya gago ya go tlolwa ga ditshwanelo tsa gago e akaretse tshedimosetso e e latelang: (1) tlhaloso ya tiro e e sireleditsweng ka ditshwanelo e go tweng e tlotswe; (2) tlhaloso ya diteng tse go tweng di tlotswe le tshedimosetso e e lekaneng go re letla go bona diteng; (3) tshedimosetso ya go ikgolaganya le wena, go akaretsa aterese ya gago, nomoro ya mogala le aterese ya imeile; (4) polelo ya gago ya gore o dumela ka pelo yotlhe gore diteng tse di tlotsweng ga di a letlelelwa ke mong wa ditshwanelo tsa gago, kgotsa moemedi wa gagwe, kgotsa ka molao ope; ']
['(5) polelo e e saenilweng ke wena, e e supang gore tshedimosetso e e mo kitsisong e boammaaruri le gore o na le thata ya go diragatsa ditshwanelo tsa botaki tse go tweng di gatakilwe;']
['le (6) saena ya mmatota kgotsa ya eleketeroniki ya mong wa tshwanelo ya go gatisa kgotsa motho yo o filweng tetla ya go dira mo boemong jwa mong wa tshwanelo ya go gatisa. ']
['Fa o sa akaretse tshedimosetso yotlhe e e fa godimo e ka nna ya diegisa go sekasekwa ga ngongorego ya gago.']
['Go Ikgolaganya']
['Tsweetswee re romelele imeile ka potso/kgakololo epe fela.']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Mo e ka nnang']
['BioMedLib e dirisa dikhomputara tse di itirisang (machine-learning algorithms) go dira dipotso le dikarabo.']
['Re simolola ka dikgatiso di le dimilione di le 35 tsa tsa kalafi ya ditshedi tsa PubMed/Medline. Gape, ditsebe tsa Web tsa RefinedWeb.']
